North America Preventive Vaccines Market 2020-2026 by Vaccine Type, Disease, Administration, Patient, and Country: COVID-19 Impact and Growth Opportunity

Report ID: 51297 | Published Date: Sep 2024 | No. of Page: 131 | Base Year: 2023 | Rating: 4.6 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Introduction	7
1.1 Industry Definition and Research Scope	7
1.1.1 Industry Definition	7
1.1.2 Research Scope	8
1.2 Research Methodology	11
1.2.1 Overview of Market Research Methodology	11
1.2.2 Market Assumption	12
1.2.3 Secondary Data	12
1.2.4 Primary Data	12
1.2.5 Data Filtration and Model Design	13
1.2.6 Market Size/Share Estimation	14
1.2.7 Research Limitations	15
1.3 Executive Summary	16
2 Market Overview and Dynamics	19
2.1 Market Size and Forecast	19
2.1.1 Impact of COVID-19 on World Economy	21
2.1.2 Impact of COVID-19 on the Market	23
2.2 Major Growth Drivers	25
2.3 Market Restraints and Challenges	28
2.4 Emerging Opportunities and Market Trends	31
2.5 Porter’s Fiver Forces Analysis	35
3 Segmentation of North America Market by Vaccine Type	39
3.1 Market Overview by Vaccine Type	39
3.2 Live/Attenuated Vaccines	41
3.3 Inactivated Vaccines	42
3.4 Subunit Vaccines	43
3.5 Toxoid Vaccines	44
3.6 Conjugate Vaccines	45
3.7 Recombinant Vector Vaccines	46
3.8 Other Vaccines	47
4 Segmentation of North America Market by Disease	48
4.1 Market Overview by Disease	48
4.2 Vaccines for Pneumococcal Disease	50
4.3 Vaccines for Poliovirus	51
4.4 Vaccines for Hepatitis	52
4.5 Vaccines for Influenza	53
4.6 Vaccines for Measles, Mumps, and Rubella (MMR)	54
4.7 Vaccines for Varicella	55
4.8 Vaccines for Human Papilloma Virus	56
4.9 Vaccines for COVID-19	57
4.10 Vaccines for Other Diseases	60
5 Segmentation of North America Market by Administration	61
5.1 Market Overview by Administration	61
5.2 Intramuscular Route	63
5.3 Subcutaneous Route	64
5.4 Oral Route	65
5.5 Intravenous Injection	66
5.6 Other Administration Routes	67
6 Segmentation of North America Market by Patient	68
6.1 Market Overview by Patient	68
6.2 Pediatric Vaccines	70
6.3 Adult Vaccines	72
7 North America Market 2020-2026 by Country	74
7.1 Overview of North America Market	74
7.2 U.S.	77
7.3 Canada	82
7.4 Mexico	85
8 Competitive Landscape	88
8.1 Overview of Key Vendors	88
8.2 New Product Launch, Partnership, Investment, and M&A	91
8.3 Company Profiles	92
AstraZeneca plc	92
Bavarian Nordic A/S	95
China National Biotec Group Company Ltd.	98
CSL Ltd.	100
Daiichi Sankyo Co. Ltd	102
Emergent BioSolutions Inc.	104
GlaxoSmithKline plc	106
Johnson & Johnson	110
Merck & Co.	112
Moderna Inc.	114
Novavax, Inc.	115
Pfizer Inc.	117
Sanofi SA	121
Takeda Pharmaceutical Co. Ltd.	123
9 Investing in North America Market: Risk Assessment and Management	125
9.1 Risk Evaluation of North America Market	125
9.2 Critical Success Factors (CSFs)	128
Related Reports and Products	131
Table 1.  Snapshot of North America Preventive Vaccines Market in Balanced Perspective, 2020-2026	17
Table 2. Growth Rate of World GDP, 2020-2022	22
Table 3.  Main Product Trends and Market Opportunities in North America Preventive Vaccines Market	31
Table 4. North America Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	39
Table 5. North America Preventive Vaccines Market by Disease, 2016-2026, $ mn	48
Table 6. COVID-19 Vaccines Authorized for Emergency Use or Approved for Full Use, as of April 2021	58
Table 7. North America Preventive Vaccines Market by Administration, 2016-2026, $ mn	61
Table 8. North America Preventive Vaccines Market by Patient, 2016-2026, $ mn	68
Table 9. North America Preventive Vaccines Market: Pediatric Vaccines by Disease, 2016-2026, $ mn	71
Table 10. North America Preventive Vaccines Market: Adult Vaccines by Disease, 2016-2026, $ mn	73
Table 11. North America Preventive Vaccines Market by Country, 2016-2026, $ mn	75
Table 12. U.S. Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	79
Table 13. U.S. Preventive Vaccines Market by Disease, 2016-2026, $ mn	79
Table 14. U.S. Preventive Vaccines Market by Administration, 2016-2026, $ mn	80
Table 15. Canada Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	83
Table 16. Canada Preventive Vaccines Market by Disease, 2016-2026, $ mn	83
Table 17. Canada Preventive Vaccines Market by Administration, 2016-2026, $ mn	84
Table 18. Mexico Preventive Vaccines Market by Vaccine Type, 2016-2026, $ mn	86
Table 19. Mexico Preventive Vaccines Market by Disease, 2016-2026, $ mn	86
Table 20. Mexico Preventive Vaccines Market by Administration, 2016-2026, $ mn	87
Table 21. AstraZeneca plc: Company Snapshot	92
Table 22. AstraZeneca plc: Revenue, 2018-2020, $ bn	93
Table 23. Bavarian Nordic A/S: Company Snapshot	95
Table 24. Bavarian Nordic A/S: Marketed Products and Pipeline, as of July 2020	96
Table 25. China National Biotec Group Company Ltd.: Company Snapshot	98
Table 26. CSL Ltd.: Company Snapshot	100
Table 27. Daiichi Sankyo Co. Ltd.: Company Snapshot	102
Table 28. Emergent BioSolutions Inc.: Company Snapshot	104
Table 29. GlaxoSmithKline: Company Snapshot	106
Table 30. GlaxoSmithKline: Business Segmentation	107
Table 31. GlaxoSmithKline: Product Portfolio	108
Table 32. GlaxoSmithKline: Revenue, 2018-2020, $ bn	109
Table 33. GlaxoSmithKline: Recent Developments	109
Table 34. Johnson & Johnson: Company Snapshot	110
Table 35. Johnson & Johnson: Business Segments	111
Table 36. Merck & Co., Inc.: Company Snapshot	112
Table 37. Merck & Co., Inc.: Business Segmentation	112
Table 38. Merck & Co., Inc.: Revenue, 2018-2020, $ bn	113
Table 39. Moderna Inc.: Company Snapshot	114
Table 40. Novavax, Inc.: Company Snapshot	115
Table 41. Pfizer Inc.: Company Snapshot	117
Table 42. Pfizer Inc.: Business Segmentation	118
Table 43. Pfizer Inc.: Product Portfolio	119
Table 44. Pfizer Inc.: Revenue, 2018-2020, $ bn	120
Table 45. Pfizer Inc.: Recent Developments	120
Table 46. Sanofi: Company Snapshot	121
Table 47. Sanofi: Business Segmentation	121
Table 48. Sanofi: Revenue, 2018-2020, $ bn	122
Table 49. Takeda Pharmaceutical Co. Ltd.: Company Snapshot	123
Table 50.  Risk Evaluation for Investing in North America Market, 2020-2026	126
Table 51. Critical Success Factors and Key Takeaways	129
Figure 1. Research Method Flow Chart	11
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation	14
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2026	16
Figure 4. North America Preventive Vaccines Market, 2016-2026, $ mn	19
Figure 5. Development Stages of Preventive Vaccines	20
Figure 6. Impact of COVID-19 on Business	23
Figure 7. Primary Drivers and Impact Factors of North America Preventive Vaccines Market	25
Figure 8. Primary Restraints and Impact Factors of North America Preventive Vaccines Market	28
Figure 9. Investment Opportunity Analysis	32
Figure 10. Porter’s Fiver Forces Analysis of North America Preventive Vaccines Market	35
Figure 11. Breakdown of North America Preventive Vaccines Market by Vaccine Type, 2020-2026, % of Revenue	40
Figure 12. Contribution to North America 2021-2026 Cumulative Revenue by Vaccine Type, Value ($ mn) and Share (%)	40
Figure 13. North America Preventive Vaccines Market: Live/Attenuated Vaccines, 2016-2026, $ mn	41
Figure 14. North America Preventive Vaccines Market: Inactivated Vaccines, 2016-2026, $ mn	42
Figure 15. North America Preventive Vaccines Market: Subunit Vaccines, 2016-2026, $ mn	43
Figure 16. North America Preventive Vaccines Market: Toxoid Vaccines, 2016-2026, $ mn	44
Figure 17. North America Preventive Vaccines Market: Conjugate Vaccines, 2016-2026, $ mn	45
Figure 18. North America Preventive Vaccines Market: Recombinant Vector Vaccines, 2016-2026, $ mn	46
Figure 19. North America Preventive Vaccines Market: Other Vaccines, 2016-2026, $ mn	47
Figure 20. Breakdown of North America Preventive Vaccines Market by Disease, 2020-2026, % of Revenue	49
Figure 21. Contribution to North America 2021-2026 Cumulative Revenue by Disease, Value ($ mn) and Share (%)	49
Figure 22. North America Preventive Vaccines Market: Vaccines for Pneumococcal Disease, 2016-2026, $ mn	50
Figure 23. North America Preventive Vaccines Market: Vaccines for Poliovirus, 2016-2026, $ mn	51
Figure 24. North America Preventive Vaccines Market: Vaccines for Hepatitis, 2016-2026, $ mn	52
Figure 25. North America Preventive Vaccines Market: Vaccines for Influenza, 2016-2026, $ mn	53
Figure 26. North America Preventive Vaccines Market: Vaccines for Measles, Mumps, and Rubella (MMR), 2016-2026, $ mn	54
Figure 27. North America Preventive Vaccines Market: Vaccines for Varicella, 2016-2026, $ mn	55
Figure 28. North America Preventive Vaccines Market: Vaccines for Human Papilloma Virus, 2016-2026, $ mn	56
Figure 29. North America Preventive Vaccines Market: Vaccines for COVID-19, 2016-2026, $ mn	57
Figure 30. North America Preventive Vaccines Market: Vaccines for Other Diseases, 2016-2026, $ mn	60
Figure 31. Breakdown of North America Preventive Vaccines Market by Administration, 2020-2026, % of Revenue	62
Figure 32. Contribution to North America 2021-2026 Cumulative Revenue by Administration, Value ($ mn) and Share (%)	62
Figure 33. North America Preventive Vaccines Market: Intramuscular Route, 2016-2026, $ mn	63
Figure 34. North America Preventive Vaccines Market: Subcutaneous Route, 2016-2026, $ mn	64
Figure 35. North America Preventive Vaccines Market: Oral Route, 2016-2026, $ mn	65
Figure 36. North America Preventive Vaccines Market: Intravenous Injection, 2016-2026, $ mn	66
Figure 37. North America Preventive Vaccines Market: Other Administration Routes, 2016-2026, $ mn	67
Figure 38. Breakdown of North America Preventive Vaccines Market by Patient, 2020-2026, % of Revenue	68
Figure 39. Contribution to North America 2021-2026 Cumulative Revenue by Patient, Value ($ mn) and Share (%)	69
Figure 40. North America Preventive Vaccines Market: Pediatric Vaccines, 2016-2026, $ mn	70
Figure 41. North America Preventive Vaccines Market: Adult Vaccines, 2016-2026, $ mn	72
Figure 42. Breakdown of North America Preventive Vaccines Market by Country, 2020 and 2026, % of Revenue	75
Figure 43. Contribution to North America 2021-2026 Cumulative Revenue by Country, Value ($ mn) and Share (%)	76
Figure 44. U.S. Preventive Vaccines Market, 2016-2026, $ mn	78
Figure 45. Canada Preventive Vaccines Market, 2016-2026, $ mn	82
Figure 46.  Preventive Vaccines Market in Mexico, 2016-2026, $ mn	85
Figure 47. Growth Stage of North America Preventive Vaccines Industry over the Forecast Period	88
Figure 48.  Top Products of AstraZeneca Based on Revenue from 2016 to 2019 (in million U.S. dollars)	93
Companies Included in Reports:
Key Players (this may not be a complete list and extra companies can be added upon request): 
AstraZeneca plc
Bavarian Nordic A/S
China National Biotec Group Company Ltd.
CSL Ltd.
Daiichi Sankyo Co. Ltd
Emergent BioSolutions Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co.
Moderna Inc.
Novavax, Inc.
Pfizer Inc.
Sanofi SA
Takeda Pharmaceutical Co. Ltd.	
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Frequently Asked Questions
North America Preventive Vaccines Market report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
North America Preventive Vaccines Market report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
North America Preventive Vaccines Market report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports